Coherus Shelves Eylea Biosimilar And Rules Out Early-Stage Biosimilar Development
Biosimilars Leader Coherus Marks New Era With Immuno-Oncology Play
Executive Summary
Coherus BioSciences, a leader and innovator in the nascent US biosimilars space, has announced plans to ditch a key biosimilar opportunity and limit overall investment, in order to direct resources to immuno-oncology.
You may also be interested in...
Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
Alvotech Kicks Off Trials For Eylea Biosimilar
Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.
Coherus Claims COVID Delays As It Axes Avastin Biosimilar Program
Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.